Nitric oxide signaling in the medial prefrontal cortex is involved in the biochemical and behavioral effects of phencyclidine

Neuropsychopharmacology

Volumn 33, Issue 8, 2008, Pages 1874-1883

  Fejgin, Kim ^a   Pålsson, Erik ^a   Wass, Caroline ^a   Svensson, Lennart ^a   Klamer, Daniel ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

cGMP; Nitric oxide; Phencyclidine; Prefrontal cortex; Prepulse inhibition; Schizophrenia

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CYCLIC GMP; GUANYLATE CYCLASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIALYSATE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MEGADOSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CYCLIC GMP; DOUBLE-BLIND METHOD; ELECTRODES, IMPLANTED; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MICRODIALYSIS; MOTOR ACTIVITY; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHENCYCLIDINE; PREFRONTAL CORTEX; QUINOXALINES; RADIOIMMUNOASSAY; SIGNAL TRANSDUCTION; STARTLE REACTION;

EID: 45149103725     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301587     Document Type: Article

References (74)

1. Adams B, Moghaddam B (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18: 5545-5554.
2. Akbarian S, Bunney Jr WE, Potkin SG, Wigal SB, Hagman JO, Sandman CA et al (1993a). Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 50: 169-177.
3. Akbarian S, Vinuela A, Kim JJ, Potkin SG, Bunney Jr WE, Jones EG (1993b). Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 50: 178-187.
4. Baba H, Suzuki T, Arai H, Emson PC (2004). Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 15: 677-680.
5. Bakshi VP, Geyer MA (1998). Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J Neurosci 18: 8394-8401.
6. Bernstein HG, Bogerts B, Keilhoff G (2005). The many faces of nitric oxide in schizophrenia. A review. Schizophr Res 78: 69-86.
7. Bird DC, Bujas-Bobanovic M, Robertson HA, Dursun SM (2001). Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase. Psychopharmacology (Berl) 155: 299-309.
8. Braff DL (1993). Information processing and attention dysfunctions in schizophrenia. Schizophr Bull 19: 233-259.
9. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978). Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15: 339-343.
10. Brown FO, Lowry JP (2003). Microelectrochemical sensors for in vivo brain analysis: an investigation of procedures for modifying Pt electrodes using Nafion. Analyst 128: 700-705.
11. Bubser M, Koch M (1994). Prepulse inhibition of the acoustic startle response of rats is reduced by 6-hydroxydopamine lesions of the medial prefrontal cortex. Psychopharmacology (Berl) 113: 487-492.
12. Clarke PB, Jakubovic A, Fibiger HC (1988). Anatomical analysis of the involvement of mesolimbocortical dopamine in the locomotor stimulant actions of d-amphetamine and apomorphine. Psychopharmacology (Berl) 96: 511-520.
13. Dalley JW, Cardinal RN, Robbins TW (2004). Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 28: 771-784.
14. Deutsch SI, Rosse RB, Paul SM, Tomasino V, Koetzner L, Morn CB et al (1996). 7-Nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviors in mice. Neuropsychopharmacology 15: 37-43.
15. Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg PB, Fearing K (1997). Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol 20: 357-363.
16. Elvevag B, Goldberg TE (2000). Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14: 1-21.
17. Fejgin K, Safonov S, Palsson E, Wass C, Engel JA, Svensson L et al (2007). The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl) 191: 377-385.
18. Franklin KBJ, Paxinos G (1996). The Mouse Brain in Stereotaxic Coordinates. Academic Press: New York.
19. Freedman R, Adler LE, Gerhardt GA, Waldo M, Baker N, Rose GM et al (1987). Neurobiological studies of sensory gating in schizophrenia. Schizophr Bull 13: 669-678.
20. Gotti S, Sica M, Viglietti-Panzica C, Panzica G (2005). Distribution of nitric oxide synthase immunoreactivity in the mouse brain. Microsc Res Tech 68: 13-35.
21. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
22. Jentsch JD, Redmond Jr DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997a). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277: 953-955.
23. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH (1997b). Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17: 92-99.
24. Johansson C, Deveney AM, Reif D, Jackson DM (1999). The neuronal selective nitric oxide inhibitor AR-R 17477, blocks some effects of phencyclidine, while having no observable behavioural effects when given alone. Pharmacol Toxicol 84: 226-233.
25. Johansson C, Jackson DM, Svensson L (1997). Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat. Psychopharmacology (Berl) 131: 167-173.
26. Johansson C, Magnusson O, Deveney AM, Jackson DM, Zhang J, Engel JA et al (1998). The nitric oxide synthase inhibitor, L-NAME, blocks certain phencyclidine-induced but not amphetamine-induced effects on behaviour and brain biochemistry in the rat. Prog Neuropsychopharmacol Biol Psychiat 22: 1341-1360.
27. Kano T, Shimizu-Sasamata M, Huang PL, Moskowitz MA, Lo EH (1998). Effects of nitric oxide synthase gene knockout on neurotransmitter release in vivo. Neuroscience 86: 695-699.
28. Karatinos J, Rosse RB, Deutsch SI (1995). The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders. Clin Neuropharmacol 18: 482-499.
29. Kelly PH, Iversen SD (1976). Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 40: 45-56.
30. Klamer D, Engel JA, Svensson L (2001). The nitric oxide synthase inhibitor, L-NAME, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl) 156: 182-186.
31. Klamer D, Engel JA, Svensson L (2004a). The neuronal selective nitric oxide synthase inhibitor, nomega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. Eur J Pharmacol 503: 103-107.
32. Klamer D, Engel JA, Svensson L (2004b). Phencyclidine-induced behaviour in mice prevented by methylene blue. Basic Clin Pharmacol Toxicol 94: 65-72.
33. Klamer D, Engel JA, Svensson L (2005a). Effects of phencyclidine on acoustic startle and prepulse inhibition in neuronal nitric oxide synthase deficient mice. Eur Neuropsychopharmacol 15: 587-590.
34. Klamer D, Palsson E, Fejgin K, Zhang J, Engel JA, Svensson L (2005b). Activation of a nitric-oxide-sensitive cAMP pathway with phencyclidine: elevated hippocampal cAMP levels are temporally associated with deficits in prepulse inhibition. Psychopharmacology (Berl) 179: 479-488.
35. Klamer D, Palsson E, Revesz A, Engel JA, Svensson L (2004c). Habituation of acoustic startle is disrupted by psychotomimetic drugs: differential dependence on dopaminergic and nitric oxide modulatory mechanisms. Psychopharmacology (Berl) 176: 440-450.
36. Laitinen JT, Laitinen KS, Tuomisto L, Airaksinen MM (1994). Differential regulation of cyclic GMP levels in the frontal cortex and the cerebellum of anesthetized rats by nitric oxide: an in vivo microdialysis study. Brain Res 668: 117-121.
37. Laitinen KS, Salovaara K, Severgnini S, Laitinen JT (1997). Regulation of cyclic GMP levels in the rat frontal cortex in vivo: effects of exogenous carbon monoxide and phosphodiesterase inhibition. Brain Res 755: 272-278.
38. Linn GS, Negi SS, Gerum SV, Javitt DC (2003). Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology (Berl) 169: 234-239.
39. Luby ED, Cohen BD, Rosenbaum G, Gottlieb LS, Kelly R (1959). Study of a new schizophrenomimetic drug - sernyl. Arch Neurol Psychiatry 81: 363-369.
40. Mansbach RS, Geyer MA (1989). Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2: 299-308.
41. McGhie A, Chapman J (1961). Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34: 103-116.
42. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
43. Palsson E, Fejgin K, Wass C, Engel JA, Svensson L, Klamer D (2007). The amino acid L-lysine blocks the disruptive effect of phencyclidine on prepulse inhibition in mice. Psychopharmacology (Berl) 192: 9-15.
44. Pepicelli O, Raiteri M, Fedele E (2004). The NOS/sGC pathway in the rat central nervous system: a microdialysis overview. Neurochem Int 45: 787-797.
45. Perry W, Geyer MA, Braff DL (1999). Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients. Arch Gen Psychiatry 56: 277-281.
46. Pifarre P, Garcia A, Mengod G (2007). Species differences in the localization of soluble guanylyl cyclase subunits in monkey and rat brain. J Comp Neurol 500: 942-957.
47. Prast H, Philippu A (2001). Nitric oxide as modulator of neuronal function. Prog Neurobiol 64: 51-68.
48. Reif A, Herterich S, Strobel A, Ehlis AC, Saur D, Jacob CP et al (2006). A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol Psychiatry 11: 286-300.
49. Rothman RB, Reid AA, Monn JA, Jacobson AE, Rice KC (1989). The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites. Mol Pharmacol 36: 887-896.
50. Santiago M, Westerink BH (1990). Characterization of the in vivo release of dopamine as recorded by different types of intracerebral microdialysis probes. Naunyn Schmiedebergs Arch Pharmacol 342: 407-414.
51. Schneider M, Koch M (2005). Behavioral and morphological alterations following neonatal excitotoxic lesions of the medial prefrontal cortex in rats. Exp Neurol 195: 185-198.
52. Schwabe K, Koch M (2004). Role of the medial prefrontal cortex in N-methyl-D-aspartate receptor antagonist induced sensorimotor gating deficit in rats. Neurosci Lett 355: 5-8.
53. Seeman P, Lasaga M (2005). Dopamine agonist action of phencyclidine. Synapse 58: 275-277.
54. Seeman P, Ko F, Tallerico T (2005). Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10: 877-883.
55. Segovia G, Mora F (1998). Role of nitric oxide in modulating the release of dopamine, glutamate, and GABA in striatum of the freely moving rat. Brain Res Bull 45: 275-279.
56. Shinkai T, Ohmori O, Hori H, Nakamura J (2002). Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol Psychiatry 7: 560-563.
57. Smith JC, Whitton PS (2000). Nitric oxide modulates N-methyl- D-aspartate-evoked serotonin release in the raphe nuclei and frontal cortex of the freely moving rat. Neurosci Lett 291: 5-8.
58. Smith JC, Whitton PS (2001). The regulation of NMDA-evoked dopamine release by nitric oxide in the frontal cortex and raphe nuclei of the freely moving rat. Brain Res 889: 57-62.
59. Southam E, Garthwaite J (1993). The nitric oxide-cyclic GMP signalling pathway in rat brain. Neuropharmacology 32: 1267-1277.
60. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC et al (2001). Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl) 158: 140-145.
61. Suzuki E, Nakaki T, Nakamura M, Miyaoka H (2003). Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. J Psychiatry Neurosci 28: 288-292.
62. Swerdlow NR, Lipska BK, Weinberger DR, Braff DL, Jaskiw GE, Geyer MA (1995). Increased sensitivity to the sensorimotor gating-disruptive effects of apomorphine after lesions of medial prefrontal cortex or ventral hippocampus in adult rats. Psychopharmacology (Berl) 122: 27-34.
63. Takahata R, Moghaddam B (2003). Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 28: 1117-1124.
64. Taneli F, Pirildar S, Akdeniz F, Uyanik BS, Ari Z (2004). Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 35: 401-405.
65. Vesely DL (1979). Phencyclidine stimulates guanylate cyclase activity. Biochem Biophys Res Commun 88: 1244-1248.
66. Wass C, Archer T, Palsson E, Fejgin K, Alexandersson A, Klamer D et al (2006a). Phencyclidine affects memory in a nitric oxide-dependent manner: working and reference memory. Behav Brain Res 174: 49-55.
67. Wass C, Archer T, Palsson E, Fejgin K, Klamer D, Engel JA et al (2006b). Effects of phencyclidine on spatial learning and memory: Nitric oxide-dependent mechanisms. Behav Brain Res 171: 147-153.
68. Wegener G, Volke V, Rosenberg R (2000). Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol 130: 575-580.
69. Wiley JL (1998). Nitric oxide synthase inhibitors attenuate phencyclidine-induced disruption of prepulse inhibition. Neuropsychopharmacology 19: 86-94.
70. Wiley JL, Kogut CP, Witherell JR (1999). Effects of acute and repeated dosing with PCP on locomotion in nNOS knockout mice. 29th Annual Meeting. Society for Neuroscience (Miami Beach: Society for Neuroscience). pp 946.
71. Wynn JK, Sergi MJ, Dawson ME, Schell AM, Green MF (2005). Sensorimotor gating, orienting and social perception in schizophrenia. Schizophr Res 73: 319-325.
72. Xing G, Chavko M, Zhang LX, Yang S, Post RM (2002). Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res 58: 21-30.
73. Yesavage JA, Freman AM (1978). Acute phencyclidine (PCP) intoxication: psychopathology and prognosis. J Clin Psychiatry 39: 664-666.
74. Yilmaz N, Herken H, Cicek HK, Celik A, Yurekli M, Akyol O (2007). Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princ Pract 16: 137-141.